转移性肾癌治疗现状与进展幻灯片.ppt

脑转移患者、未控制的高血压或在入组前12个月有显著临床意义心血管事件或疾病的患者不符合纳入标准。 所有患者签署书面同意书。 根据基线乳酸脱氢酶水平(1.5 vs. ≤1.5 倍正常值上限)、ECOG 全身状态评分 (0 vs. 1)、 以前是否行肾切除 (是 vs. 不是)对患者进行随机分层 。患者按照 1:1 的比例随机入组分别接受舒尼替尼或干扰素-治疗。随机区组数为4 以在分层情况下平衡各组患者。 Patients in the SUTENT? group reported significantly better health-related quality of life (QoL) (P.001) than patients in the interferon alfa group in post-baseline assessments using the Functional Assessment of Cancer Therapy-General(FACT-G) questionnaire. In fact, patients who received interferon alfa had a significant drop in their QoL from the beginning of therapy, and this difference remained throughout the course of therapy. SUTENT was consistently associated with a significantly improved QoL. FACT-G is a validated tool used to evaluate health-related quality of life in cancer patients. This is a 28-item questionnaire that can easily be completed in 5 minutes, usually without assistance. Agree this is better. Also, I think the log–rank p values should be included here, since they represents survival comparisons over the entire study period, not just median survival. I would like Steve’s opinion on this. 未来 RCC的治疗将会是… 进一步探索生物学靶标 血管生成抑制剂: Axitinib (AG-013736), vatalanib (PTK-787, ZK-222584) ,Pazopanib, Cediranib (AZD-2171) EGFR 受体抑制剂: cetuximab, gefitinib, GW016 mTOR 抑制剂: Everolimus, ARIAD Pharmaceuticals (AP-23573) 蛋白酶体抑制剂: bortezomib 靶向药物的联合,与化疗及免疫治疗的联合 单克隆抗体 cG250 疫苗类 dendritic cell-based 我科dendritic cell-based疫苗尝试 欢迎访问 下载最新资料 谢谢! Advanced RCC: prognosis Although surgery may be curative, a high proportion of patients with RCC develop metastatic disease, and long-term survival is low for those with advanced disease A 5-year survival rate of 9.5% has been reported for patients with metastatic RCC. National Cancer Institute. SEER Cancer Statistics Review 1975–2003. Available at /csr/1975_2003/results_merged/sect_11_kidney_pelvis.pdf. Accessed 25 May 2006. Interval less than 1 year (in cytokine pretreated) No of metastatic locations RCC: Unmet